Circulating Tumor Cell Market Share Driven by Advances in Liquid Biopsy and Precision Oncology | Valuates Reports

Circulating Tumor Cell Market Size
The global market for Circulating Tumor Cell was valued at US$ 774 million in the year 2024 and is projected to reach a revised size of US$ 1309 million by 2031, growing at a CAGR of 7.9% during the forecast period.

View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-36G5969/Global_Circulating_Tumor_Cell_Market_Insights_Forecast_to_2028

The Circulating Tumor Cell (CTC) Market is experiencing significant growth due to the rising demand for non-invasive cancer diagnostic technologies and advancements in precision oncology. Circulating tumor cells are cancer cells that detach from primary tumors and circulate in the bloodstream, making them valuable biomarkers for early cancer detection, disease monitoring, and treatment evaluation. CTC analysis is widely used in liquid biopsy approaches, which allow clinicians to monitor cancer progression and treatment response without invasive tissue biopsies. With the growing focus on personalized medicine and early cancer diagnosis, the global CTC market is expected to expand steadily during the forecast period.

Based on type segmentation, the market includes CTC enrichment, CTC detection, and CTC analysis technologies. CTC enrichment technologies are used to isolate and concentrate rare circulating tumor cells from blood samples, which is a critical step due to the extremely low number of CTCs in circulation. CTC detection technologies enable the identification of these isolated cells using advanced imaging, molecular markers, or antibody-based techniques. CTC analysis involves genetic and molecular characterization of circulating tumor cells, helping clinicians understand tumor biology, detect mutations, and guide targeted cancer therapies.

In terms of application, breast cancer represents one of the largest application segments for circulating tumor cell technologies due to the extensive research and clinical adoption of CTC testing for disease monitoring and treatment decision-making. Prostate cancer is another major segment where CTC analysis is increasingly used to assess tumor progression and evaluate therapy effectiveness. Colorectal cancer also contributes significantly to market growth as liquid biopsy techniques gain wider acceptance in oncology diagnostics. Other cancer types, including lung, pancreatic, and gastric cancers, are also being explored for CTC-based diagnostic and monitoring applications.

Several biotechnology and diagnostics companies are active in the circulating tumor cell market. Key industry participants include Menarini Silicon Biosystems, QIAGEN, Clearbridge Biomedics, and Celsee. Other notable companies include Fluidigm, ApoCell, Greiner Bio-One, Advanced Cell Diagnostics, Aviva Biosciences, Fluxion Biosciences, Sysmex, Epic Sciences, Cynvenio Biosystems, CytoTrack, Ikonisys, Vortex BioSciences, Gilupi, Biocept, ScreenCell, and ANGLE plc. These companies are investing in advanced microfluidics, molecular analysis tools, and AI-based diagnostic platforms to improve the sensitivity and clinical utility of CTC technologies.

From a regional perspective, North America dominates the circulating tumor cell market due to strong research funding, advanced healthcare infrastructure, and early adoption of liquid biopsy technologies. Europe also holds a significant market share supported by increasing investments in cancer research and precision medicine initiatives. Meanwhile, the Asia-Pacific region is expected to experience rapid growth due to expanding healthcare infrastructure, rising cancer incidence, and growing investment in biotechnology research in countries such as China, Japan, South Korea, and India. Emerging healthcare markets in Latin America and the Middle East & Africa are also gradually adopting advanced cancer diagnostic technologies, further supporting the growth of the global circulating tumor cell market.

Segment by Type

• CTC Enrichment
• CTC Detection
• CTC Analysis

Segment by Application

• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Others

By Company

Menarini-Silicon Biosystems, Qiagen(Adnagen), Clearbridge Biomedics, Celsee, Fluidigm, ApoCell, Greiner Bio-one, Advanced Cell Diagnostics, Aviva Biosciences, Fluxion Biosciences, Sysmex, Epic Sciences, Cynvenio, CytoTrack, Ikonisys, Vortex BioSciences, Gilupi, Biocept, ScreenCell, ANGLE

View full report
https://reports.valuates.com/market-reports/QYRE-Auto-36G5969/global-circulating-tumor-cell

Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066,

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.